Systemic amyloidosis following inflammatory bowel disease, follicular lymphoma, and diffuse large B-cell lymphoma: a case report
DOI:
https://doi.org/10.13181/mji.cr.247428Keywords:
amyloidosis, diffuse large B-cell lymphoma, follicular lymphoma, gastrointestinal tract, inflammatory bowel diseaseAbstract
Systemic amyloidosis is a rare disorder characterized by the widespread deposition of misfolded amyloid proteins in several organs, leading to organ failure and potentially death if not promptly recognized. The occurrence of inflammatory bowel disease (IBD), follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL) developing into systemic amyloidosis is uncommon. Here is a case of a 55-year-old Asian woman with a history of IBD, follicular lymphoma, and abdominal DLBCL who developed systemic amyloidosis affecting her gastrointestinal, cardiac, and renal organs. Gastrointestinal symptoms (abdominal pain and melena) initially manifested in this patient with systemic amyloidosis. She underwent treatment with three cycles of rituximab and bendamustine. However, she passed away after 2 months of hospitalization due to multiple organ failure. Hence, physicians must be vigilant in recognizing amyloidosis as a potential complication of lymphoma or other inflammatory diseases, as early recognition can contribute to improved clinical outcomes.
Downloads
References
Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848-60. https://doi.org/10.1002/ajh.25819
la Torre A, Reece D, Crump M, Atenafu EG, Chen C, Prica A, et al. Light chain amyloidosis (AL) associated with B cell lymphoma a single center experience. Clin Lymphoma Myeloma Leuk. 2021;21(12):e946-59. https://doi.org/10.1016/j.clml.2021.07.003
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79-89. https://doi.org/10.1001/jama.2020.5493
Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046-53. https://doi.org/10.1182/bloodadvances.2018016402
Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol. 2006;81(9):692-5. https://doi.org/10.1002/ajh.20635
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-54. https://doi.org/10.1016/S0140-6736(15)01274-X
Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369-77. https://doi.org/10.2147/CLEP.S39981
Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620-7. https://doi.org/10.1182/blood.2020006913
Telio D, Bailey D, Chen C, Crump M, Reece D, Kukreti V. Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature. Am J Hematol. 2010;85(10):805-8. https://doi.org/10.1002/ajh.21814
Alves P, Góis M, Mendes M, Sousa H, Sousa J, Nolasco F. Non-Hodgkin lymphoma-associated AA amyloidosis. J Onco-Nephrol. 2020;4(3):92-5. https://doi.org/10.1177/2399369320929340
Matsumoto Y, Masuda T, Nishimura A, Horie H, Harada K, Yoshida M, et al. A case of AL amyloidosis associated with follicular lymphoma with plasmacytic differentiation. Int J Hematol. 2020;111(2):317-23. https://doi.org/10.1007/s12185-019-02734-7
Sharma P, Aguilar R, Siddiqui OA, Nader MA. Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis. Ann Gastroenterol. 2017;30(5):504-11. https://doi.org/10.20524/aog.2017.0168
Kadota T, Seo S, Fuse H, Ishii G, Itoh K, Yano T, et al. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP. Cancer Med. 2019;8(3):982-9. https://doi.org/10.1002/cam4.1982
Goteri G, Lucarini G, Zizzi A, Costagliola A, Giantomassi F, Stramazzotti D, et al. Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas. Diagn Pathol. 2011;6:97. https://doi.org/10.1186/1746-1596-6-97
Cho J. Basic immunohistochemistry for lymphoma diagnosis. Blood Res. 2022;57(S1):55-61. https://doi.org/10.5045/br.2022.2022037
Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635-42. https://doi.org/10.1182/blood-2014-07-575373
Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, et al. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018;32(2):353-63. https://doi.org/10.1038/leu.2017.222
Lee AS, Lee DZ, Vasanwala FF. Amyloid light-chain amyloidosis presenting as abdominal bloating: a case report. J Med Case Rep. 2016;10:68. https://doi.org/10.1186/s13256-016-0857-z
Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-80.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Lugyanti Sukrisman, Dadang Makmun, Ening Krisnuhoni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
